drugset / Trial / NCT07758608
Renal Impairment Pharmacokinetics (PK) Trial of Afabicin
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to assess the effect of renal impairment on the PK of afabicin desphosphono after a single oral 80 milligrams (mg) or intravenous (IV) 55 mg dose of afabicin.
Timeline
- Start
- 2026-09
- Primary completion
- 2027-12
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Afabicin | Small molecule | 55 mg | Intravenous |
| Comparator | Afabicin | Small molecule | 80 mg | Oral |